Patents Assigned to Exiqon A/S
-
Patent number: 10023912Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.Type: GrantFiled: December 4, 2015Date of Patent: July 17, 2018Assignee: EXIQON A/SInventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
-
Publication number: 20180044737Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, miR-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, miR-374b-5p, miR-615-3p and miR-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.Type: ApplicationFiled: February 26, 2016Publication date: February 15, 2018Applicant: Exiqon A/SInventors: Anni RØNFELDT THOMSEN, Helle KRISTENSEN, Karina DALSGAARD SØRENSEN, Lars KONGSBAK, Peter MOURITZEN, Torben ØRNTOFT
-
Patent number: 9464106Abstract: The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample.Type: GrantFiled: November 14, 2011Date of Patent: October 11, 2016Assignee: Exiqon A/SInventors: Sakari Kauppinen, Carsten Alsbo, Peter S. Nielsen, Daniel C. Jeffares, Tobias Mourier, Søren Mørk, Peter Arctander, Niels Tommerup, Niels Tolstrup, Henrik Vissing, Søren Morgenthaler Echwald
-
Patent number: 9212390Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.Type: GrantFiled: April 28, 2011Date of Patent: December 15, 2015Assignee: EXIQON A/SInventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
-
Patent number: 9096895Abstract: The present invention relates to a method for amplification and quantification of microRNA molecules using quantitative reverse transcription polymerase chain reaction (qRT-PCR) technology. The method comprise the steps of (a) producing cDNA molecules complementary' to microRNAs in a sample using polyadenylation and primer extension by reverse transcription, and (b) amplification and quantification of the cDNAs by qPCR using microRNA specific primer sets of forward and reverse primers containing LNA monomers.Type: GrantFiled: February 2, 2010Date of Patent: August 4, 2015Assignee: EXIQON A/SInventor: Peter Kamp Busk
-
Publication number: 20140227689Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: ApplicationFiled: February 25, 2013Publication date: August 14, 2014Applicant: Exiqon A/SInventor: Exiqon A/S
-
Publication number: 20130164750Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.Type: ApplicationFiled: April 28, 2011Publication date: June 27, 2013Applicant: EXIQON A/SInventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
-
Patent number: 8383344Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: GrantFiled: June 1, 2009Date of Patent: February 26, 2013Assignee: Exiqon A/SInventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
-
Publication number: 20120184603Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.Type: ApplicationFiled: March 30, 2012Publication date: July 19, 2012Applicant: Exiqon A/SInventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
-
Publication number: 20120157333Abstract: The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample.Type: ApplicationFiled: November 14, 2011Publication date: June 21, 2012Applicant: Exiqon A/SInventors: Sakari Kauppinen, Carsten Alsbo, Peter S. Nielsen, Daniel C. Jeffares, Tobias Mourier, Søren Mørk, Peter Arctander, Niels Tommerup, Niels Tolstrup, Henrik Vissing, Søren Morgenthaler Echwald
-
Patent number: 8192937Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: GrantFiled: April 7, 2005Date of Patent: June 5, 2012Assignee: Exiqon A/SInventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
-
Patent number: 8188255Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.Type: GrantFiled: October 19, 2007Date of Patent: May 29, 2012Assignee: Exiqon A/SInventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
-
Patent number: 8153365Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: June 3, 2010Date of Patent: April 10, 2012Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20120071332Abstract: The present invention relates to a method for amplification and quantification of microRNA molecules using quantitative reverse transcription polymerase chain reaction (qRT-PCR) technology. The method comprise the steps of (a) producing cDNA molecules complementary to microRNAs in a sample using polyadenylation and primer extension by reverse transcription, and (b) amplification and quantification of the cDNAs by qPCR using microRNA specific primer sets of forward and reverse primers containing LNA monomers.Type: ApplicationFiled: February 2, 2010Publication date: March 22, 2012Applicant: Exiqon A/SInventor: Peter Kamp Busk
-
Patent number: 8080644Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: August 13, 2008Date of Patent: December 20, 2011Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 8048998Abstract: The present invention relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those.Type: GrantFiled: January 18, 2008Date of Patent: November 1, 2011Assignee: Exiqon A/SInventors: Soeren Vestergaard Rasmussen, Torsten Bryld, Soeren Moeller
-
Patent number: 8034909Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: August 15, 2008Date of Patent: October 11, 2011Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20110245327Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: June 3, 2010Publication date: October 6, 2011Applicant: Exiqon A/SInventors: Jesper WENGEL, Poul Nielsen
-
Publication number: 20110076675Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.Type: ApplicationFiled: June 1, 2009Publication date: March 31, 2011Applicant: EXIQON A/SInventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
-
Patent number: RE44779Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.Type: GrantFiled: June 26, 2012Date of Patent: February 25, 2014Assignees: Santaris Pharma A/S, Exiqon A/SInventors: Takeshi Imanishi, Satoshi Obika